229 search results for Calcium
| # | SuperPathway Name | Genes Count | Relevance Score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CREB Pathway | 529 | 2.281 | |||||||
|
||||||||||
| 2 | DREAM Repression and Dynorphin Expression | 250 | 2.119 | |||||||
|
||||||||||
| 3 | Mitochondrial calcium ion transport | 23 | 1.940 | |||||||
|
||||||||||
| 4 | Activation of cAMP-Dependent PKA | 632 | 1.732 | |||||||
|
||||||||||
| 5 | NFAT and Cardiac Hypertrophy | 326 | 1.706 | |||||||
|
||||||||||
| 6 | Myometrial relaxation and contraction pathways | 215 | 1.687 | |||||||
|
||||||||||
| 7 | Transmission across Chemical Synapses | 410 | 1.680 | |||||||
|
||||||||||
| 8 | Sweet Taste Signaling | 365 | 1.653 | |||||||
|
||||||||||
| 9 | Development Ligand-independent activation of ESR1 and ESR2 | 135 | 1.653 | |||||||
|
||||||||||
| 10 | TCR Signaling (Qiagen) | 238 | 1.626 | |||||||
|
||||||||||
| 11 | ERK Signaling | 1185 | 1.626 | |||||||
|
||||||||||
| 12 | Integrin Pathway | 570 | 1.626 | |||||||
|
||||||||||
| 13 | PKC-gamma calcium signaling pathway in ataxia | 22 | 1.573 | |||||||
|
||||||||||
| 14 | MIF Mediated Glucocorticoid Regulation | 681 | 1.543 | |||||||
|
||||||||||
| 15 | G-Beta Gamma Signaling | 219 | 1.543 | |||||||
|
||||||||||
| 16 | Presenilin-Mediated Signaling | 142 | 1.514 | |||||||
|
||||||||||
| 17 | CCR5 Pathway in Macrophages | 321 | 1.514 | |||||||
|
||||||||||
| 18 | Fc-GammaR Pathway | 84 | 1.514 | |||||||
|
||||||||||
| 19 | Apoptotic Pathways in Synovial Fibroblasts | 731 | 1.514 | |||||||
|
||||||||||
| 20 | Immune response Function of MEF2 in T lymphocytes | 124 | 1.478 | |||||||
|
||||||||||
| 21 | Transport of inorganic cations/anions and amino acids/oligopeptides | 728 | 1.466 | |||||||
|
||||||||||
| 22 | Platelet homeostasis | 88 | 1.466 | |||||||
|
||||||||||
| 23 | MAPK signaling pathway | 244 | 1.455 | |||||||
|
||||||||||
| 24 | Calmodulin induced events | 118 | 1.415 | |||||||
|
||||||||||
| 25 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 978 | 1.361 | |||||||
|
||||||||||
| 26 | Dopamine-DARPP32 Feedback onto cAMP Pathway | 228 | 1.361 | |||||||
|
||||||||||
| 27 | Innate Immune System | 2025 | 1.328 | |||||||
|
||||||||||
| 28 | Cardiac conduction | 232 | 1.294 | |||||||
|
||||||||||
| 29 | Vitamin D-sensitive calcium signaling in depression | 34 | 1.276 | |||||||
|
||||||||||
| 30 | Ca, cAMP and Lipid Signaling | 126 | 1.260 | |||||||
|
||||||||||
| 31 | Celecoxib Pathway, Pharmacodynamics | 58 | 1.260 | |||||||
|
||||||||||
| 32 | Signal Transduction | 2590 | 1.150 | |||||||
|
||||||||||
| 33 | Nervous system development | 1168 | 1.111 | |||||||
|
||||||||||
| 34 | Neuroscience | 341 | 1.029 | |||||||
|
||||||||||
| 35 | Olfactory Signaling Pathway | 621 | 1.029 | |||||||
|
||||||||||
| 36 | Phase 0 - rapid depolarisation | 34 | 1.029 | |||||||
|
||||||||||
| 37 | Netrin Signaling | 49 | 1.029 | |||||||
|
||||||||||
| 38 | Neuropathic Pain-Signaling in Dorsal Horn Neurons | 232 | 0.985 | |||||||
|
||||||||||
| 39 | ADORA2B mediated anti-inflammatory cytokines production | 419 | 0.985 | |||||||
|
||||||||||
| 40 | NCAM signaling for neurite out-growth | 63 | 0.939 | |||||||
|
||||||||||
| 41 | Sensory processing of sound | 76 | 0.939 | |||||||
|
||||||||||
| 42 | Response to elevated platelet cytosolic Ca2+ | 621 | 0.939 | |||||||
|
||||||||||
| 43 | B Cell Receptor Signaling Pathway | 148 | 0.939 | |||||||
|
||||||||||
| 44 | Activation of NMDA receptors and postsynaptic events | 93 | 0.891 | |||||||
|
||||||||||
| 45 | MAPK-Erk Pathway | 275 | 0.891 | |||||||
|
||||||||||
| 46 | Potassium Channels | 103 | 0.891 | |||||||
|
||||||||||
| 47 | Trafficking of AMPA receptors | 31 | 0.840 | |||||||
|
||||||||||
| 48 | Development Angiotensin activation of ERK | 225 | 0.840 | |||||||
|
||||||||||
| 49 | Vitamin D receptor pathway | 185 | 0.840 | |||||||
|
||||||||||
| 50 | Development EGFR signaling pathway | 154 | 0.840 | |||||||
|
||||||||||
| 51 | GPCR downstream signalling | 710 | 0.840 | |||||||
|
||||||||||
| 52 | Infectious disease | 1747 | 0.840 | |||||||
|
||||||||||
| 53 | Acetylcholine binding and downstream events | 15 | 0.814 | |||||||
|
||||||||||
| 54 | Integration of energy metabolism | 108 | 0.786 | |||||||
|
||||||||||
| 55 | PIP3 activates AKT signaling | 310 | 0.786 | |||||||
|
||||||||||
| 56 | Neuroinflammation and glutamatergic signaling | 140 | 0.786 | |||||||
|
||||||||||
| 57 | Prolactin Signaling | 432 | 0.786 | |||||||
|
||||||||||
| 58 | GPCR Pathway | 712 | 0.786 | |||||||
|
||||||||||
| 59 | Metabolism | 2121 | 0.786 | |||||||
|
||||||||||
| 60 | Class I MHC mediated antigen processing and presentation | 855 | 0.786 | |||||||
|
||||||||||
| 61 | G-AlphaQ Signaling | 216 | 0.786 | |||||||
|
||||||||||
| 62 | Unblocking of NMDA receptors, glutamate binding and activation | 40 | 0.727 | |||||||
|
||||||||||
| 63 | Cytokine Signaling in Immune system | 732 | 0.727 | |||||||
|
||||||||||
| 64 | Disturbed pathways in Duchenne Muscular Dystrophy | 26 | 0.727 | |||||||
|
||||||||||
| 65 | Beta-Adrenergic Signaling | 333 | 0.664 | |||||||
|
||||||||||
| 66 | Thromboxane signalling through TP receptor | 96 | 0.664 | |||||||
|
||||||||||
| 67 | Gene expression (Transcription) | 1546 | 0.664 | |||||||
|
||||||||||
| 68 | Transcriptional Regulation by MECP2 | 62 | 0.664 | |||||||
|
||||||||||
| 69 | MyD88 dependent cascade initiated on endosome | 175 | 0.664 | |||||||
|
||||||||||
| 70 | Nitric oxide stimulates guanylate cyclase | 22 | 0.664 | |||||||
|
||||||||||
| 71 | Translation Translation regulation by Alpha-1 adrenergic receptors | 74 | 0.664 | |||||||
|
||||||||||
| 72 | Antiarrhythmic Pathway, Pharmacodynamics | 55 | 0.664 | |||||||
|
||||||||||
| 73 | MAPK Signaling: Oxidative Stress | 79 | 0.664 | |||||||
|
||||||||||
| 74 | Visual Cycle in Retinal Rods | 94 | 0.664 | |||||||
|
||||||||||
| 75 | Hepatic ABC Transporters | 88 | 0.664 | |||||||
|
||||||||||
| 76 | Development Endothelin-1/EDNRA transactivation of EGFR | 115 | 0.664 | |||||||
|
||||||||||
| 77 | Sympathetic Nerve Pathway (Pre- and Post- Ganglionic Junction) | 12 | 0.664 | |||||||
|
||||||||||
| 78 | Beta-2 adrenergic-dependent CFTR expression | 167 | 0.664 | |||||||
|
||||||||||
| 79 | HSF1-dependent transactivation | 24 | 0.594 | |||||||
|
||||||||||
| 80 | Alzheimer's disease and miRNA effects | 267 | 0.594 | |||||||
|
||||||||||
| 81 | Ion channel transport | 186 | 0.594 | |||||||
|
||||||||||
| 82 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 32 | 0.594 | |||||||
|
||||||||||
| 83 | AMP-activated protein kinase signaling | 100 | 0.594 | |||||||
|
||||||||||
| 84 | WNT Signaling | 250 | 0.594 | |||||||
|
||||||||||
| 85 | Cellular response to heat stress | 89 | 0.594 | |||||||
|
||||||||||
| 86 | Cellular responses to stimuli | 802 | 0.594 | |||||||
|
||||||||||
| 87 | Oncogenic MAPK signaling | 84 | 0.594 | |||||||
|
||||||||||
| 88 | CD28 Signaling in T-Helper Cell | 113 | 0.594 | |||||||
|
||||||||||
| 89 | Defensins | 95 | 0.594 | |||||||
|
||||||||||
| 90 | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 29 | 0.594 | |||||||
|
||||||||||
| 91 | Development Dopamine D2 receptor transactivation of EGFR | 128 | 0.594 | |||||||
|
||||||||||
| 92 | NO/cGMP/PKG mediated neuroprotection | 44 | 0.594 | |||||||
|
||||||||||
| 93 | Fragile X syndrome | 120 | 0.594 | |||||||
|
||||||||||
| 94 | ncRNAs involved in Wnt signaling in hepatocellular carcinoma | 220 | 0.594 | |||||||
|
||||||||||
| 95 | Signaling downstream of RAS mutants | 83 | 0.594 | |||||||
|
||||||||||
| 96 | LGI-ADAM interactions | 14 | 0.594 | |||||||
|
||||||||||
| 97 | Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics | 12 | 0.594 | |||||||
|
||||||||||
| 98 | Immune response_IFN gamma signaling pathway | 63 | 0.594 | |||||||
|
||||||||||
| 99 | Signal transduction_Erk Interactions- Inhibition of Erk | 74 | 0.594 | |||||||
|
||||||||||
| 100 | RAF/MAP kinase cascade | 571 | 0.594 | |||||||
|
||||||||||
| 101 | Sympathetic Nerve Pathway (Neuroeffector Junction) | 23 | 0.594 | |||||||
|
||||||||||
| 102 | Interferon gamma signaling | 203 | 0.594 | |||||||
|
||||||||||
| 103 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | 51 | 0.576 | |||||||
|
||||||||||
| 104 | Diseases of Immune System | 57 | 0.514 | |||||||
|
||||||||||
| 105 | GDNF signaling | 132 | 0.514 | |||||||
|
||||||||||
| 106 | Smooth Muscle Contraction | 45 | 0.514 | |||||||
|
||||||||||
| 107 | Hepatocyte growth factor receptor signaling | 115 | 0.514 | |||||||
|
||||||||||
| 108 | CAMKK2 pathway | 31 | 0.514 | |||||||
|
||||||||||
| 109 | BDNF-TrkB signaling | 46 | 0.514 | |||||||
|
||||||||||
| 110 | Antigen processing-Cross presentation | 105 | 0.514 | |||||||
|
||||||||||
| 111 | Splicing factor NOVA regulated synaptic proteins | 39 | 0.514 | |||||||
|
||||||||||
| 112 | Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics | 28 | 0.514 | |||||||
|
||||||||||
| 113 | Non-Canonical Wnt Pathway | 59 | 0.514 | |||||||
|
||||||||||
| 114 | Burn wound healing | 75 | 0.514 | |||||||
|
||||||||||
| 115 | Sensory perception of taste | 60 | 0.514 | |||||||
|
||||||||||
| 116 | Valproic Acid Pathway, Pharmacodynamics | 19 | 0.514 | |||||||
|
||||||||||
| 117 | Activation of AMPK downstream of NMDARs | 84 | 0.420 | |||||||
|
||||||||||
| 118 | Signaling events mediated by HDAC Class I | 118 | 0.420 | |||||||
|
||||||||||
| 119 | Clear cell renal cell carcinoma pathways | 85 | 0.420 | |||||||
|
||||||||||
| 120 | Signaling by Receptor Tyrosine Kinases | 524 | 0.420 | |||||||
|
||||||||||
| 121 | Disruption of postsynaptic signaling by CNV | 17 | 0.420 | |||||||
|
||||||||||
| 122 | Common pathways underlying drug addiction | 41 | 0.420 | |||||||
|
||||||||||
| 123 | Signaling by Rho GTPases | 722 | 0.420 | |||||||
|
||||||||||
| 124 | Interleukin-1 family signaling | 153 | 0.420 | |||||||
|
||||||||||
| 125 | PI3K-Akt signaling pathway | 390 | 0.420 | |||||||
|
||||||||||
| 126 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 110 | 0.420 | |||||||
|
||||||||||
| 127 | Prostaglandin synthesis and regulation | 56 | 0.420 | |||||||
|
||||||||||
| 128 | Energy metabolism | 47 | 0.420 | |||||||
|
||||||||||
| 129 | Nicotine effect on chromaffin cells | 4 | 0.420 | |||||||
|
||||||||||
| 130 | TCR signaling in naïve CD4+ T cells | 65 | 0.420 | |||||||
|
||||||||||
| 131 | MTOR signalling | 55 | 0.420 | |||||||
|
||||||||||
| 132 | Regulation of nuclear beta catenin signaling and target gene transcription | 72 | 0.420 | |||||||
|
||||||||||
| 133 | RHO GTPases Activate NADPH Oxidases | 24 | 0.420 | |||||||
|
||||||||||
| 134 | Glucose / Energy Metabolism | 307 | 0.420 | |||||||
|
||||||||||
| 135 | Advanced glycosylation endproduct receptor signaling | 13 | 0.420 | |||||||
|
||||||||||
| 136 | Gastric cancer network 1 | 29 | 0.420 | |||||||
|
||||||||||
| 137 | Synaptic vesicle pathway | 51 | 0.420 | |||||||
|
||||||||||
| 138 | Corticotropin-releasing hormone signaling pathway | 91 | 0.420 | |||||||
|
||||||||||
| 139 | Neural Stem Cells and Lineage-specific Markers | 79 | 0.297 | |||||||
|
||||||||||
| 140 | GPCRs, class C metabotropic glutamate, pheromone | 21 | 0.297 | |||||||
|
||||||||||
| 141 | Angiopoietin-like protein 8 regulatory pathway | 194 | 0.297 | |||||||
|
||||||||||
| 142 | Endochondral ossification with skeletal dysplasias | 63 | 0.297 | |||||||
|
||||||||||
| 143 | Non-integrin membrane-ECM interactions | 82 | 0.297 | |||||||
|
||||||||||
| 144 | Blood-Brain Barrier and Immune Cell Transmigration: Overview | 71 | 0.297 | |||||||
|
||||||||||
| 145 | Regulation of Ras family activation | 27 | 0.297 | |||||||
|
||||||||||
| 146 | Fertilization | 25 | 0.297 | |||||||
|
||||||||||
| 147 | Autophagy pathway | 228 | 0.297 | |||||||
|
||||||||||
| 148 | Physico-chemical features and toxicity-associated pathways | 65 | 0.297 | |||||||
|
||||||||||
| 149 | Adhesion | 123 | 0.297 | |||||||
|
||||||||||
| 150 | p73 transcription factor network | 76 | 0.297 | |||||||
|
||||||||||
| 151 | Non-genomic actions of 1,25 dihydroxyvitamin D3 | 51 | 0.297 | |||||||
|
||||||||||
| 152 | Microtubule cytoskeleton regulation | 46 | 0.297 | |||||||
|
||||||||||
| 153 | LKB1 signaling events | 37 | 0.297 | |||||||
|
||||||||||
| 154 | TGF-beta receptor signaling | 50 | 0.297 | |||||||
|
||||||||||
| 155 | Cardiomyocyte signaling pathways converging on Titin | 13 | 0.297 | |||||||
|
||||||||||
| 156 | Opioid receptor pathways | 6 | 0.297 | |||||||
|
||||||||||
| 157 | FGF signaling pathway | 54 | 0.297 | |||||||
|
||||||||||
| 158 | Syndecan-2-mediated signaling events | 34 | 0.297 | |||||||
|
||||||||||
| 159 | mTOR Signaling | 139 | 0.297 | |||||||
|
||||||||||
| 160 | Primary focal segmental glomerulosclerosis (FSGS) | 72 | 0.297 | |||||||
|
||||||||||
| 161 | Ciliary landscape | 212 | 0.297 | |||||||
|
||||||||||
| 162 | Protein-protein interactions at synapses | 86 | 0.297 | |||||||
|
||||||||||
| 163 | Validated transcriptional targets of deltaNp63 isoforms | 47 | 0.297 | |||||||
|
||||||||||
| 164 | Nuclear receptors meta-pathway | 315 | 0.297 | |||||||
|
||||||||||
| 165 | p38 MAPK signaling pathway (Pathway Interaction Database) | 19 | 0.297 | |||||||
|
||||||||||
| 166 | CFTR-dependent regulation of ion channels in Airway Epithelium (norm and CF) | 35 | 0.297 | |||||||
|
||||||||||
| 167 | Peroxisomal lipid metabolism | 167 | 0.297 | |||||||
|
||||||||||
| 168 | Netrin-1 signaling | 60 | 0.297 | |||||||
|
||||||||||
| 169 | Meiosis | 152 | 0.297 | |||||||
|
||||||||||
| 170 | Signaling by Hedgehog | 149 | 0.297 | |||||||
|
||||||||||
| 171 | DNA Damage | 296 | 0.297 | |||||||
|
||||||||||
| 172 | Transcriptional activation of mitochondrial biogenesis | 95 | 0.297 | |||||||
|
||||||||||
| 173 | Vesicle-mediated transport | 673 | 0.297 | |||||||
|
||||||||||
| 174 | Dravet syndrome | 30 | 0.297 | |||||||
|
||||||||||
| 175 | E-cadherin signaling in keratinocytes | 18 | 0.297 | |||||||
|
||||||||||
| 176 | Regulation of CFTR activity (norm and CF) | 106 | 0.297 | |||||||
|
||||||||||
| 177 | MicroRNAs in cardiomyocyte hypertrophy | 112 | 0.297 | |||||||
|
||||||||||
| 178 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | 36 | 0.297 | |||||||
|
||||||||||
| 179 | BAFF in B-Cell Signaling | 84 | 0.297 | |||||||
|
||||||||||
| 180 | Estradiol regulation in porto-sinusoidal vascular disease | 7 | 0.297 | |||||||
|
||||||||||
| 181 | Signaling by WNT | 331 | 0.297 | |||||||
|
||||||||||
| 182 | Gastric cancer network 2 | 31 | 0.297 | |||||||
|
||||||||||
| 183 | 17q12 copy number variation syndrome | 99 | 0.297 | |||||||
|
||||||||||
| 184 | Validated transcriptional targets of TAp63 isoforms | 54 | 0.297 | |||||||
|
||||||||||
| 185 | Melatonin metabolism and effects | 31 | 0.297 | |||||||
|
||||||||||
| 186 | Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling | 104 | 0.297 | |||||||
|
||||||||||
| 187 | Metabolism of proteins | 1970 | 0.297 | |||||||
|
||||||||||
| 188 | Neurotransmitter release cycle | 51 | 0.297 | |||||||
|
||||||||||
| 189 | Signaling by NTRKs | 134 | 0.297 | |||||||
|
||||||||||
| 190 | Sertoli-Sertoli Cell Junction Dynamics | 393 | 0.297 | |||||||
|
||||||||||
| 191 | Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 0.297 | |||||||
|
||||||||||
| 192 | AMPK Enzyme Complex Pathway | 153 | 0.297 | |||||||
|
||||||||||
| 193 | Organelle biogenesis and maintenance | 296 | 0.297 | |||||||
|
||||||||||
| 194 | Noncanonical Wnt signaling pathway | 26 | 0.297 | |||||||
|
||||||||||
| 195 | Bardet-Biedl syndrome | 103 | 0.297 | |||||||
|
||||||||||
| 196 | VEGFA-VEGFR2 signaling | 154 | 0.297 | |||||||
|
||||||||||
| 197 | Phospholipase-C Pathway | 503 | 0.297 | |||||||
|
||||||||||
| 198 | Processing of Capped Intron-Containing Pre-mRNA | 745 | 0.297 | |||||||
|
||||||||||
| 199 | Signaling by ERBB4 | 70 | 0.297 | |||||||
|
||||||||||
| 200 | Class A/1 (Rhodopsin-like receptors) | 556 | 0.297 | |||||||
|
||||||||||
| 201 | Dissolution of Fibrin Clot | 13 | 0.297 | |||||||
|
||||||||||
| 202 | Phosphodiesterases in neuronal function | 52 | 0.297 | |||||||
|
||||||||||
| 203 | MECP2 and associated Rett syndrome | 73 | 0.297 | |||||||
|
||||||||||
| 204 | Validated targets of C-MYC transcriptional repression | 62 | 0.297 | |||||||
|
||||||||||
| 205 | Direct p53 effectors | 128 | 0.297 | |||||||
|
||||||||||
| 206 | Syndecan-3-mediated signaling events | 20 | 0.297 | |||||||
|
||||||||||
| 207 | Syndecan-1-mediated signaling events | 30 | 0.297 | |||||||
|
||||||||||
| 208 | Glucocorticoid receptor pathway | 71 | 0.297 | |||||||
|
||||||||||
| 209 | BCR signaling pathway | 65 | 0.297 | |||||||
|
||||||||||
| 210 | Genetic causes of porto-sinusoidal vascular disease | 36 | 0.297 | |||||||
|
||||||||||
| 211 | Serotonin and anxiety | 20 | 0.297 | |||||||
|
||||||||||
| 212 | N-cadherin signaling events | 30 | 0.297 | |||||||
|
||||||||||
| 213 | Proton Pump Inhibitor Pathway, Pharmacodynamics | 45 | 0.297 | |||||||
|
||||||||||
| 214 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 125 | 0.297 | |||||||
|
||||||||||
| 215 | Aminoglycoside Ototoxicity Pathway, Adverse Drug Reaction | 18 | 0.297 | |||||||
|
||||||||||
| 216 | Nephrin family interactions | 23 | 0.297 | |||||||
|
||||||||||
| 217 | Malignant pleural mesothelioma | 409 | 0.297 | |||||||
|
||||||||||
| 218 | Regulation of CDH11 Expression and Function | 145 | 0.297 | |||||||
|
||||||||||
| 219 | Nuclear Events (kinase and transcription factor activation) | 61 | 0.297 | |||||||
|
||||||||||
| 220 | IL1 and megakaryocytes in obesity | 24 | 0.297 | |||||||
|
||||||||||
| 221 | Type II diabetes mellitus | 22 | 0.297 | |||||||
|
||||||||||
| 222 | Notch-mediated HES/HEY network | 45 | 0.297 | |||||||
|
||||||||||
| 223 | Extracellular matrix organization | 300 | 0.297 | |||||||
|
||||||||||
| 224 | Signaling events mediated by VEGFR1 and VEGFR2 | 63 | 0.297 | |||||||
|
||||||||||
| 225 | Proteoglycan biosynthesis | 18 | 0.297 | |||||||
|
||||||||||
| 226 | Validated nuclear estrogen receptor alpha network | 65 | 0.297 | |||||||
|
||||||||||
| 227 | SRF and miRs in smooth muscle differentiation and proliferation | 11 | 0.297 | |||||||
|
||||||||||
| 228 | Regucalcin in proximal tubule epithelial kidney cells | 22 | 0.297 | |||||||
|
||||||||||
| 229 | Physiological and pathological hypertrophy of the heart | 23 | 0.297 | |||||||
|
||||||||||